1. Introduction
===============

Human respiratory syncytial virus (RSV) belongs to the genus *Pneumovirus* in the subfamily *Pneumovirinae* of the family *Paramyxoviridae*, and is a major causative agent of respiratory tract infections in children worldwide. Children born preterm or with underlying cardiopulmonary disorders are at especially high risk of developing severe and lethal RSV respiratory tract infections ([@bib1]; [@bib10], [@bib24], [@bib25]). Elderly and immunocompromised individuals are also susceptible to severe respiratory diseases, highlighting the importance of preventing nasocomial and in-house RSV infections in hospitals and care centers for the elderly ([@bib4], [@bib7]). Palivizumab, a monoclonal antibody with neutralizing activity against RSV, was developed recently and made available commercially as an effective prophylaxis against disease ([@bib1]). Thus, precise diagnostic and epidemiological tests are important for the prevention of RSV infections.

The diagnosis of RSV infection is generally undertaken by virus isolation and/or antigen detection using an enzyme immunoassay (EIA) ([@bib3], [@bib6], [@bib23]). However, because of the thermolability of RSV, the rate of isolation is dependent on conditions such as sample collection and cold chain from sample collection to cell inoculation. EIAs are useful as bed-side diagnostic tools in clinical settings, however their sensitivity and specificity are generally between 70 and 90%, suggesting that misdiagnosis of RSV infection is common (10--30%) ([@bib11], [@bib19], [@bib29]). In addition, it is difficult to detect RSV antigen in nasopharyngeal aspirates collected from adults, since only a small amount of RSV antigen can be found ([@bib2], [@bib6], [@bib7]). The development of more sensitive and specific detection methods is therefore essential for more precise diagnoses of RSV. As a result, molecular methods such as reverse transcription (RT)-polymerase chain reaction (PCR) and quantitative real-time RT-PCR have been developed for the detection of RSV ([@bib6], [@bib5], [@bib8]).

Loop-mediated isothermal amplification (LAMP) was developed recently to amplify specific nucleic acid sequences using a designated primer set ([@bib16], [@bib17]). Amplification by LAMP is simple, since the reaction mixture is incubated at a single temperature for less than 1 h, and specificity is high because at least six specific primer region sequences are required for construction of the LAMP primer set ([@bib16], [@bib17]). The amplified product level can be monitored in a real-time quantitative manner by measuring turbidity since nucleic acid amplification results in the precipitation of magnesium pyrophosphate ([@bib14]). The LAMP assay can also be used with RNA templates by combining reverse transcription reactions with LAMP (RT-LAMP) ([@bib17]). Genetic diagnosis by RT-LAMP has been developed for infections caused by RNA viruses, such as severe acute respiratory syndrome (SARS), West Nile encephalitis, and Dengue fever ([@bib13], [@bib22], [@bib21]).

[@bib27] recently developed RT-LAMP for detection of the RSV genome and the primers used in their method were designed according to the nucleotide sequence of the nucleoprotein region. Highly conserved sequences of the nucleotide sequence are located in the matrix protein region of RSV isolates, suggesting that this region was a suitable target for designing LAMP primers. In the present study, a RT-LAMP method was developed in which the LAMP primers were designed from the matrix protein gene, and the competence of this assay was compared to virus isolation and EIA.

2. Materials and methods
========================

2.1. Specimen and virus isolation
---------------------------------

59 nasopharyngeal aspirates were collected from children with respiratory tract infections from November 2004 to November 2005 at Sendai Medical Center, Sendai, Japan. Nasopharyngeal aspirates were suspended in transport medium containing Eagle\'s minimum essential medium (MEM, Invitrogen Corp., Carlsbad, CA, USA) supplemented with 0.5% of gelatin, and antibiotics ([@bib18]) and stored at −20 °C prior to use. The nasopharyngeal aspirates were centrifuged at 3000 rpm for 15 min, and the supernatant was used for virus isolation. Detection of RSV antigen was analyzed in 46 of the 59 nasopharyngeal aspirates using the enzyme immunoassay (EIA), BD Directigen EZ RSV test™ (Becton, Dickinson and Company, Franklin Lakes, NJ, USA). The nasopharyngeal aspirates were also used for RNA extraction. Virus isolation was performed using six kinds of cells, MDCK, HEp-2, Vero, HMV-II, LLC-MK2, and human embryo fibroblasts, by seeding them in 96-well plate as described previously ([@bib18], [@bib26]).

2.2. Viruses
------------

The RSV strains used in this study were laboratory strains (Long and CH-18537) and wild type viruses isolated in 1996 (N96-77, N97-23, N91-730, N96-51, and N96-728). Human metapneumovirus was isolated in the Virus Research Center at Sendai Medical Center (hMPV; 2003--2404), human coronaviruses (HCoV) strain NL63 was supplied by Dr. Hoek (University of Amsterdam, the Netherlands), HCoV strain 229E was supplied by Dr. Nomura (FUJITA Health University, Japan), SARS coronavirus strain Frankfurt was supplied by Dr. J. Ziebuhr (University of Würzburg, Germany), parainfluenza virus 3 was purchased from the American Tissue Culture Collection (ATCC) (C-245), influenza viruses strains A:H5N1, A:H3N2, A:H1N1, and B were stored in the National Institute of Infectious Diseases in Japan, and adenoviruses serotype 3, strain O.B., serotype 4, strain R163, and serotype 7, strain Gomen were stored in National Institute of Infectious Diseases in Japan. Bacterial pathogens that induce respiratory tract infections, like *Bordetella pertussis* (Tohama), *Bordetella parapertussis* (ATCC15311), *Haemophils influenza* biotype 3, *Haemophils parainfluenza* biotype 1, and *Mycoplasma pneumonia* (M129), were also stored in NIID. RSV was propagated in HEp-2 cells and titrated using the standard plaque assay on HEp-2 cells cultured in 12-well culture plates.

2.3. Design of primer sets for RT-LAMP
--------------------------------------

RSV strains are divided into two subgroups (A and B) based on antigenic variation ([@bib9], [@bib15]). The primer sets for the RT-LAMP assay were designed from the alignment sequences of three subgroup A RSV strains (GenBank accession Nos. [NC_001803](NC_001803), [U39662](U39662), [U50362](U50362)) and three subgroup B RSV strains ([NC_001781](NC_001781), [AF013254](AF013254), and [AY353550](AY353550)) using the online LAMP primer design software (PrimerExplorer; <http://primerexplorer.jp/index.html>). The loop primer set was also designed with this software. The RSV RT-LAMP primer set described by [@bib27] was also used for experiments.

2.4. Extraction of RNA and DNA
------------------------------

RNA was extracted from virus stocks using TRIzol reagent (Invitrogen), according to the manufacturer\'s instructions. DNA was extracted from stocks of adenovirus or bacteria using QIAGEN Genomic-tips (Qiagen, Hilden, Germany) according to the manufacturer\'s instructions. RNA was extracted from 140 μl of each nasopharyngeal aspirate and eluted with 50 μl of elute buffer using the QIAamp Viral RNA Mini Kit (Qiagen). Total RNA and genomic DNA were quantitated by measuring the OD value.

2.5. RT-LAMP assay and RT-PCR
-----------------------------

The RT-LAMP assay was performed using the Loopamp RNA amplification reagents kit (RT-LAMP; Eiken, Tokyo, Japan) as described. 5 μl of each sample of extracted RNA or DNA was mixed with 40 pmol of the FIP and BIP primers, 20 pmol of the Loop-F and Loop-B primers, 5 pmol of the F3 and B3 primers, 1 μl of Enzyme Mix, and 12.5 μl of Reaction Mix, and distilled water was added to make a final volume of 25 μl. For real-time monitoring of the RT-LAMP assay, the reaction mixture was incubated at 63 °C for 45 min in the Loopamp real-time turbidimeter (LA-200; Teramecs, Kyoto, Japan). A no template negative control was included in each assay. For the purposes of this study, samples in which the magnitude of the turbidity signal was greater than 0.1 within 45 min were considered positive. Time during which the turbidity was greater than 0.1 was expressed as time of positivity in minutes. The minimum copy number of the target regions produced using the RT-LAMP assay was determined from the RT-PCR product. Target regions of the RT-LAMP assay were amplified with specific primers and Platinum *Taq* High Fidelity DNA polymerase (Invitrogen). The PCR products were gel-purified with a QIAquick Gel Purification Kit (Qiagen) and the concentration was determined by measuring the OD value. The DNA copy number was calculated using the following formula: copies (number/ml) = ((6.023 × l0^23^  × 5 × l0^−5^  × OD~260~)/molecular weight). RT-LAMP assay was performed using serially diluted target DNA, and the copy number detection limit was determined.

One-step RT-PCR was also carried out to detect RSV from clinical specimens as described. 5 μl of each sample was mixed with 1 μl of each primer set (sense: GARGTRGCTCCAGAATAYAGGCAT, anti-sense: AGCATCACTTGCCCTGAACCATAG; [@bib20]), 25.0 μl of 2× AccessQuik RT-PCR Master Mix (Promega Corporation, Madison, WI, USA), and 1 μl of supplemented RT enzyme, and distilled water was added to make a final volume of 50 μl. The amplification program consisted of an RT step at 45 °C for 45 min, followed by a denature step at 94 °C for 2 min, and 30 cycles of 93 °C for 30 s, 55 °C for 30 s, and 72 °C for 50 s, with a final extension step of 72 °C for 7 min ([@bib12]). After amplification, amplicons were separated by electrophoresis on a 2% agarose gel, stained with ethidium bromide, and the bands were visualized under ultraviolet light.

2.6. Confirmation of RSV subgroup A and B
-----------------------------------------

RT-LAMP products were purified using the QIAquick PCR Purification Kit (Qiagen), and the purified amplicons were digested with the restriction enzyme, *Nla*III or *Xba*I, under optimal conditions (New England Biolabs, Ipswich, MA, USA). After 2 h of digestion, RT-LAMP products were separated by electrophoresis on a 3% agarose gel, stained with ethidium bromide, and the bands were visualized under ultraviolet light. The amplicon from subgroup A RSV was digested with *Nla*III, while that from subgroup B RSV was digested with *Xba*I.

3. Results
==========

3.1. RT-LAMP primer design
--------------------------

The primer sets used in this study are shown in [Table 1](#tbl1){ref-type="table"} . The primer set for RT-LAMP was first designed with the aim of amplifying both the A and B subgroups of RSV. This proved difficult to design, however, because the LAMP assay uses at least six specific primer regions. Thus, primer sets were designed that had specificity for subgroup A RSV (primer set A) or subgroup B RSV (primer set B). Based on alignment analysis of RSV genomic sequences, highly conserved sequences in the matrix protein coding region were selected as the target genomic sequence ([Fig. 1](#fig1){ref-type="fig"} ).Table 1Primer sets used in the RT-LAMP assayPrimerPosition[a](#tbl1fn1){ref-type="table-fn"}Sequence (5′--3′)Primer set A RSAM-F33224--3246GGGGCAAATATGGAAACATACGT RSAM-B33438--3421GAAGGTCCATTGGGTGTG RSAM-FIP (Flc + F2)3319--3296 + 3255--3272AGGGTCATCGTCTTTTTCTAAGACAttttTTCACGAAGGCTCCACAT RSAM-BIP (Blc + B2)3322--3343 + 3404--3382ATCACTTACAATATGGGTGCCCttttGTATGTTGACATTAGCTAGTTCT RSAM-Loop F3295--3273TTGTATTGAACAGCAGCTGTGT RSAM-Loop B3359--3379ATGCCAGCAGATTTACTTATA  Primer set B RSBM-F33254--3275GGGCAAATATGGAAACATACG RSBM-B33462--3445CCTTTGGGCGTAGAGATC RSBM-FIP (Flc + F2)3360--3336 + 3276--3294GTTAGTGATGCAGGATCATCATCTTttttTGAACAAGCTTCACGAAGG RSBM-BIP (Blc + B2)3363--3383 + 3443--3422TATGGGTGCCTATGTTCCAGTttttGCTTCACTAGTATGTTGATGCT RSBM-Loop F3322--3301GTACTGAACAGCTGCTGTGTAT RSBM-Loop B3395--3419GCAGACTTGCTCATAAAAGAACTTG[^1]Fig. 1Location of the RT-LAMP primer region. RT-LAMP primer sets were designed using PrimerExplorer online software. The position of six essential primers (F3, F2, F1, B1, B2, and B3) and the loop primer regions are shown by lines and bold font. Underlined sequences illustrate the recognition site of each restriction enzyme (CATG of *Nla*III and ACATGT of *Xba*I).

A negative control using water was analyzed by RT-LAMP for 60 min to define the value of the turbidity signal that would discriminate positives from negatives in the RT-LAMP assay. None of the negative controls had a turbidity signal that was greater than 0.1 within a 45 min reaction time. Thus, turbidity values exceeding 0.1 within the 45 min reaction time were defined as positive.

3.2. Specificity and sensitivity of the RT-LAMP assay
-----------------------------------------------------

Specific reactions of the designed primer set were tested on various respiratory pathogens ([Table 2](#tbl2){ref-type="table"} ). The RT-LAMP assay was performed using 100 ng of total RNA or 1 ng of extracted genomic DNA. The RT-LAMP using primer set A and primer set B were only able to detect subgroup A RSV and subgroup B RSV, respectively. Samples prepared from other respiratory pathogens, including human coronaviruses, influenza viruses, metapneumovirus, adenoviruses, and bacteria, showed a negative reaction by RT-LAMP. Importantly, these pathogens were positive by PCR or RT-PCR when primer sets were used that were specific for each organism (data not shown). Thus, the primer set described in this report specifically reacts with RSV. Amplicons were digested with the restriction enzyme *Nla*III or *Xba*I and separated by electrophoresis on a 3% agarose gel to confirm specific amplification and differentiation of subgroups A and B. As predicted, the RT-LAMP products amplified from subgroup A RSV were only digested with *Nla*III, while the products amplified from subgroup B RSV were only digested with *Xba*I (data not shown).Table 2Specificity of the RT-LAMP assayPathogenStrainPrimer setSubgroup ASubgroup BRNA viruses Respiratory syncytial viruslong (A)13.7 ± 0.5\>45.0CH-18537 (B)\>45.020.2 ± 0.2   Viruses isolated from clinical samplesN96-77 (A)17.8 ± 0.5\>45.0N97-23 (A)20.1 ± 0.7\>45.0N91-730(B)\>45.015.4 ± 0.4N96-51 (B)\>45.014.2 ± 0.7N96-728 (B)\>45.014.6 ± 0.9   Metapneumovirus2003--2404\>45.0\>45.0   Human coronavirusNL63\>45.0\>45.0229E\>45.0\>45.0   SARS coronavirusFrankfurt\>45.0\>45.0 Parainfluenza virus 3C-245\>45.0\>45.0   Influenza virusA/VN/JP1203/04 H5N1\>45.0\>45.0A/Panama/2007/97 H3N2\>45.0\>45.0A/NC H1N1\>45.0\>45.0B/Shanghai/361/2002\>45.0\>45.0  DNA virus AdenovirusType 3 (O.B.)\>45.0\>45.0Type 4 (R163)\>45.0\>45.0Type 7 (Gomen)\>45.0\>45.0  Bacteria Bordetella pertussisTohama\>45.0\>45.0 Bordetella parapertussisATCC15311\>45.0\>45.0 Haemophils influenza (biotype 3)\>45.0\>45.0 Haemophils parainfluenza (biotype 1)\>45.0\>45.0 Mycoplasma pneumoniaM129\>45.0\>45.0[^2]

The sensitivity of RT-LAMP was next evaluated using serially diluted RNA samples prepared from an RSV stock ([Table 3](#tbl3){ref-type="table"} ). The infectivity of the RSV stock was determined by plaque assay using HEp-2 cells prior to RNA extraction. The entire process of preparing the samples including virus propagation, virus titration, RNA extraction, and the RT-LAMP assay, were carried out three times independently. 10^−1^ to 10^−2^ PFU of RSV was required to provide enough RNA for detection using the RT-LAMP assay. The detection limit of nucleic acid copy number was determined using PCR products of the target region as a template. At least 10^2^  copies/5 μl of the template were required for detection by RT-LAMP (data not shown).Table 3Sensitivity of the RT-LAMP assayPFU (log)3210−1−2−3Lot l Long13.415.116.318.524.728.0\>45 CH-1853714.617.918.924.033.8\>45\>45  Lot 2 Long15.717.218.822.223.934.3\>45 CH-1853714.115.317.320.029.339.6\>45  Lot 3 Long21.824.42729.742.3\>45\>45 CH-1853712.713.916.518.522.932.5\>45[^3]

The RT-LAMP assay was carried out using a mixed sample of subgroups A and B RSV to evaluate potential interference between them. RT-LAMP was able to differentiate between RSV subgroups, and each primer set detected specifically its own target subgroup (data not shown).

3.3. Amplification of the RSV genome from nasopharyngeal aspirates using RT-LAMP
--------------------------------------------------------------------------------

RT-LAMP assay was performed to evaluate whether the primer set used in this study could detect RSV in clinical specimens using 59 nasopharyngeal aspirates from children with respiratory tract infections, and the results were compared with those obtained using virus isolation and the EIA test, BD Directigen EZ RSV test ([Table 4](#tbl4){ref-type="table"} ). 61% (36/59) were positive by RT-LAMP, 34% (20/59) by viral isolation, 56% (26/46) by EZ RSV, and 58% (34/59) by RT-PCR. The success rate of RSV detection using the RT-LAMP assay was higher than virus isolation and the EIA test. Of the 39 RSV isolation-negative samples, 4 had parainfluenza virus, 3 had influenza virus, and 1 had enterovirus. These other respiratory viruses isolated were RT-LAMP-negative except for one influenza virus-positive specimen that was RSV positive using the primer set described above as well as the primer set reported by Ushio et al. Comparison between the ability of EZ RSV, RSV isolation, and the RT-LAMP assay to detect RSV from clinical specimens is shown in [Table 5](#tbl5){ref-type="table"} . Of the 20 RSV isolation-positive specimens, 100% (20/20) were positive by RT-LAMP and 80% were positive (16/20) by EZ RSV. Of the 26 RSV isolation-negative specimens, 42% (11/26) were positive by RT-LAMP and 35% (9/26) by EZ RSV. The sensitivity of RT-PCR was similar to that of EIA. However, 12.5% (2/16) of specimens that were both antigen detection and virus isolation negative were positive by RT-LAMP.Table 4Success rate of RSV detection in clinical nasopharyngeal aspiratesNumber of tested specimensRSV positiveRSV negativePercent of positiveRSV isolation59203934% (20/59)EZ RSV46262057% (26/46)RT-PCR59342558% (34/59)RT-LAMP59362361% (36/59)Table 5Ability of EZ RSV, RSV isolation, and the RT-LAMP assay to detect RSV detection from clinical specimensRT-PCRRT-LAMP assayPositiveNegativePositiveNegativeRSV isolation positive (*n* = 20)200200 EZ RSV positive (*n* = 16)160160 EZ RSV negative (*n* = 4)4040  RSV isolation negative (*n* = 26)9171115 EZ RSV positive (*n* = 10)9191 EZ RSV negative (*n* = 16)016214

4. Discussion
=============

This paper describes a highly sensitive and specific genetic diagnostic method that can detect human RSV using the RT-LAMP assay. Subgroup A and B RSV were both detected by RT-LAMP using primer sets A or B, while other respiratory pathogens were not. The assay developed in this study can detect viral RNA in 10^−1^ to 10^−2^ PFU of RSV. RSV was also detected in nasopharyngeal aspirates from children with respiratory tract infections, suggesting that the RSV RT-LAMP developed in the present study may be used for diagnosing RSV infections in children.

RSV infections are usually detected by virus isolation or EIAs. The virus isolation method, however, is only able to detect infectious virus. RSV is thermolabile and the quantity of infectious particles depends on sample preparation and storage conditions. Thus, isolation of RSV can be difficult and RSV infection runs the risk of being overlooked if this is the only method used. EIA kits do not require infectious viral antigens for detection and can be carried out easily in a short time (approximately 15 min), and are considered useful for general clinical diagnosis of young children ([@bib19], [@bib29]). However, misdiagnosis can occur in 10--30% of RSV infections when the EIA kit is used alone ([@bib11]). RSV is not detected easily in specimens from adult patients using either virus isolation or the EIA kit, because neutralizing antibodies maintain the virus titer low ([@bib2], [@bib6], [@bib7]). Molecular diagnostic methods can detect viruses as long as genomic sequences exist, regardless of the integrity of the virus particle. As a result, molecular diagnostics method should be undertaken for definitive diagnosis of RSV. The LAMP assay is simpler and quicker than RT-PCR ([@bib13], [@bib22]), and results can be obtained by viewing fluorescence or determining turbidity values without opening the sample tubes, minimizing concerns about contaminating amplified products. In addition, expensive fluorescent probes and detection instruments that are required for real-time PCR, are unnecessary for the LAMP assay. Therefore, the LAMP assay is useful for qualitative detection of RSV, and RT-LAMP can be used to amplify quantitatively the virus genome in real-time ([@bib13]). The RT-LAMP assay may be useful not only for diagnostic tests but also for prognosis. In this study, nasopharyngeal aspirates were collected from children with respiratory tract infections, and RT-LAMP was able to detect the RSV genome. The RT-LAMP assay developed in this study also detected RSV genomes in samples that were negative by virus isolation and EIA, suggesting that RT-LAMP is a more sensitive assay for the detection of RSV antigens and is more useful in diagnosing RSV infections than classical methods. The RT-LAMP assay may also be used for diagnosing RSV infections in adults, although further studies are required to test this. In this study, supernatants of nasopharyngeal aspirates were used to detect RSV using the RT-LAMP assay. Since some paramyxovirus virions are cell associated ([@bib28]), this assay may be even more sensitive if the cells are not spun out.

Of the clinical specimens, one was RT-LAMP positive using the RSV primer sets described above and the primer set described by [@bib27] as well as being RSV isolation negative, and EIA negative. Viral isolation was influenza virus positive, however, so it is thought that this specimen may have been co-infected with both viruses. Perhaps the RSV gene was present in such small amounts that it could only be detected using the RT-LAMP assay.

Recently, [@bib27] developed a diagnostic method for detecting the RSV genome using RT-LAMP using the nucleoprotein region sequences as primers. However, the specificity of this method of RSV detection was only tested against three influenza virus strains. In contrast, we examined the specificity of the RT-LAMP technique against multiple respiratory pathogens, including metapneumovirus, influenza viruses, human coronaviruses, adenoviruses, and bacteria, and found that they were not amplified. When clinical specimens were tested using the RT-LAMP primer set described above and that described by [@bib27] RSV genome detection was comparable. Thus, the sensitivity of our RT-LAMP assay described is equivalent to Ushio\'s method (2005). Since RSV is a negative strand RNA virus that develops frequent mutations, two or more primer sets may be preferable for diagnosis. The RT-LAMP assay presented in this report should aid laboratory diagnosis and epidemiological surveillance of RSV infection.
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[^1]: RSV subgroup A virus, GenBank accession No. [NC_001803](NC_001803); subgroup B virus, [NC_001781](NC_001781).

[^2]: Time of positivity in minutes.

[^3]: Time of positivity in minutes.
